Brooks O'Neil
Stock Analyst at Lake Street
(1.25)
# 3,388
Out of 4,711 analysts
28
Total ratings
39.29%
Success rate
-12.9%
Average return
Main Sectors:
Stocks Rated by Brooks O'Neil
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LFVN LifeVantage | Initiates: Buy | $26 | $17.36 | +49.77% | 1 | Dec 19, 2024 | |
| LFMD LifeMD | Initiates: Buy | $12 | $5.04 | +138.10% | 1 | Dec 10, 2024 | |
| HROW Harrow | Maintains: Buy | $45 → $55 | $34.22 | +60.72% | 3 | Oct 4, 2024 | |
| MODV ModivCare | Maintains: Buy | $50 → $30 | $11.13 | +169.54% | 2 | Sep 17, 2024 | |
| ATEC Alphatec Holdings | Maintains: Buy | $32 → $18 | $9.35 | +92.51% | 4 | Sep 3, 2024 | |
| ORGO Organogenesis Holdings | Initiates: Buy | $5 | $3.05 | +63.93% | 1 | Jun 28, 2024 | |
| SRDX Surmodics | Downgrades: Hold | $43 | $39.75 | +8.18% | 3 | May 29, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Buy | $60 → $75 | $35.91 | +108.86% | 1 | May 22, 2024 | |
| PIII P3 Health Partners | Maintains: Buy | $9 → $4.5 | $0.20 | +2,180.79% | 1 | Mar 14, 2024 | |
| MDXG MiMedx Group | Initiates: Buy | $12 | $9.10 | +31.87% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $75 | $92.12 | -18.58% | 1 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $40 | $11.77 | +239.85% | 5 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $26 | $27.74 | -6.27% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $45 | $3.39 | +1,227.43% | 1 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $1.39 | +691.37% | 1 | Apr 8, 2022 |
LifeVantage
Dec 19, 2024
Initiates: Buy
Price Target: $26
Current: $17.36
Upside: +49.77%
LifeMD
Dec 10, 2024
Initiates: Buy
Price Target: $12
Current: $5.04
Upside: +138.10%
Harrow
Oct 4, 2024
Maintains: Buy
Price Target: $45 → $55
Current: $34.22
Upside: +60.72%
ModivCare
Sep 17, 2024
Maintains: Buy
Price Target: $50 → $30
Current: $11.13
Upside: +169.54%
Alphatec Holdings
Sep 3, 2024
Maintains: Buy
Price Target: $32 → $18
Current: $9.35
Upside: +92.51%
Organogenesis Holdings
Jun 28, 2024
Initiates: Buy
Price Target: $5
Current: $3.05
Upside: +63.93%
Surmodics
May 29, 2024
Downgrades: Hold
Price Target: $43
Current: $39.75
Upside: +8.18%
Tandem Diabetes Care
May 22, 2024
Maintains: Buy
Price Target: $60 → $75
Current: $35.91
Upside: +108.86%
P3 Health Partners
Mar 14, 2024
Maintains: Buy
Price Target: $9 → $4.5
Current: $0.20
Upside: +2,180.79%
MiMedx Group
Mar 7, 2024
Initiates: Buy
Price Target: $12
Current: $9.10
Upside: +31.87%
Aug 2, 2023
Maintains: Buy
Price Target: $65 → $75
Current: $92.12
Upside: -18.58%
Jul 13, 2023
Maintains: Buy
Price Target: $30 → $40
Current: $11.77
Upside: +239.85%
Feb 15, 2023
Maintains: Buy
Price Target: $20 → $26
Current: $27.74
Upside: -6.27%
Nov 21, 2022
Assumes: Buy
Price Target: $45
Current: $3.39
Upside: +1,227.43%
Apr 8, 2022
Initiates: Buy
Price Target: $11
Current: $1.39
Upside: +691.37%